Alector’s AL001 Fast Track’d in U.S. for type of dementia

The FDA designates Alector’s (NASDAQ:ALEC) lead candidate AL001 for Fast Track review for the treatment of frontotemporal dementia (FTD), a group of brain disorders characterized by atrophy in the lobes of the brain in those areas.

Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.

AL001 is an intravenously administered humanized recombinant monoclonal antibody designed to increase levels of a protein called progranulin in the brain. Mutations in the encoding gene can reduce granulin levels by as much as 70%. In these cases, the probability of developing FTD is greater than 90%.

https://seekingalpha.com/news/3524217-alectors-al001-fast-trackd-in-u-s-for-type-of-dementia